Pharmacyclics Inc. ( PCYC ) was a big mover last session, as its shares rose over 16% on the day. The upside has been driven by the company's release of preliminary Q4 revenue figure which outshines the Zacks Consensus Estimate. The 2015 outlook provided by the company also holds considerable promise. This led to more shares changing hands than in a normal session. Yesterday's rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $119.85 to $133.34 in the past one-month time frame.
Over the last 30 days, this company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pharmacyclics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
A better-ranked med-dugs stock is BioCryst Pharmaceuticals, Inc. ( BCRX ) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report